Intratympanic treatment of hearing loss with novel and traditional agents

Otolaryngologic Clinics of North America

Volumn 37, Issue 5, 2004, Pages 973-990

  Seidman, Michael D ^a,b   Vivek, Prashant ^a  

^a HENRY FORD HOSPITAL   (United States)

^b West Bloomfield MI 48323 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ALLOPURINOL; ALPHA TOCOPHEROL; ANTIOXIDANT; ASCORBIC ACID; CALPASTATIN; CISPLATIN; CORTICOSTEROID; DEXAMETHASONE; DIURETIC AGENT; GENTAMICIN; GLUTAMATE RECEPTOR ANTAGONIST; IRON CHELATING AGENT; LEVACECARNINE; LIDOCAINE; MACROGOL; METHIONINE; METHYLPREDNISOLONE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLETHANOLAMINE; PHOSPHOLIPID; RESVERATROL; SALICYLIC ACID; STEROID; STREPTOMYCIN; SUPEROXIDE DISMUTASE; THIOCTIC ACID; TRIMETHYLTIN; UNINDEXED DRUG;

CLINICAL TRIAL; DISEASE EXACERBATION; DRUG ACTIVITY; DRUG EFFECT; DRUG MECHANISM; GENE THERAPY; HEARING LOSS; HUMAN; MEDICAL PRACTICE; MENIERE DISEASE; MITOCHONDRION; MOLECULAR DYNAMICS; MOLECULAR INTERACTION; NONHUMAN; OTOTOXICITY; PERCEPTION DEAFNESS; PHARMACEUTICAL CARE; PROTEIN FAMILY; PROTEIN FUNCTION; REVIEW; SIDE EFFECT; TINNITUS; TREATMENT OUTCOME;

ADMINISTRATION, TOPICAL; ANIMALS; ANTIOXIDANTS; CYSTEINE PROTEINASE INHIBITORS; EXCITATORY AMINO ACID ANTAGONISTS; GENE THERAPY; GLUCOCORTICOIDS; GLYCOPROTEINS; HEARING LOSS; HUMANS; NERVE GROWTH FACTORS; PHOSPHATIDYLCHOLINES; ROUND WINDOW; TYMPANIC MEMBRANE;

EID: 5044233739     PISSN: 00306665     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.otc.2004.03.005     Document Type: Review

References (164)

1. Fact sheet on noise-induced hearing loss. 1998;National Institute on Deafness and other Communication Disorders, Washington (DC)
2. Cruickshanks K.J., Wiley T.L., Twee T.S., et al. Prevalence of hearing loss in older adults in Beaver Dam, Wisconsin: The Epidemiology of Hearing Loss Study. Am J Epidemiol. 148:(9):1998;879-886
3. Johns M., Brackmann D.E., Kimmelman C., et al. Goals and mechanisms for training otolaryngologists in the area of geriatric medicine. Otolaryngol Head Neck Surg. 100:(4):1989;262-265
4. Kopke R.D., Hoffer M.E., Wester D., et al. Targeted topical steroid therapy in sudden sensorineural hearing loss. Otol Neurotol. 22:(4):2001;475-479
5. Kastenbauer S., Klein M., Koedel U., et al. Reactive nitrogen species contribute to blood labyrinth barrier disruption in suppurative labyrinthitis complicating experimental pneumococcal meningitis in the rat. Brain Res. 904:(2):2001;208-217
6. Clerici W.J., Hensley K., DiMartino D.L., et al. Direct detection of ototoxicant induced reactive oxygen species generation in cochlear explants. Hear Res. 98:(1-2):1996;116-124
7. Korver K.D., Rybak L.P., Whitworth C., et al. Round window application of D-methionine provides complete cisplatin otoprotection. Otolaryngol Head Neck Surg. 126:(6):2002;683-689
8. Ohinata Y., Yamasoba T., Schacht J., et al. Glutathione limits noise-induced hearing loss. Hear Res. 146:(1-2):2000;28-34
9. Feghali J.G., Liu W., Van De Water T.R. L-N-acetyl-cysteine protection against cisplatin-induced auditory neuronal and hair cell toxicity. Laryngoscope. 111:(7):2001;1147-1155
10. Nam Y.J., Stover T., Hartman S.S., et al. Upregulation of glial cell line-derived neurotrophic factor (GDNF) in the rat cochlea following noise. Hear Res. 146:(1-2):2000;1-6
11. Zadeh M.H., Storper I.S., Spitzer J.B. Diagnosis and treatment of sudden-onset sensorineural hearing loss: a study of 51 patients. Otolaryngol Head Neck Surg. 128:(1):2003;92-98
12. Santos P.M., Hall R.A., Snyder J.M., et al. Diuretic and diet effect on Meniere's disease evaluated by the 1985 Committee on Hearing and Equilibrium guidelines. Otolaryngol Head Neck Surg. 109:(4):1993;680-689
13. Redleaf M.I., Bauer C.A., Gantz B.J., et al. Diatrizoate and dextran treatment of sudden sensorineural hearing loss. Am J Otol. 16:(3):1995;295-303
14. Kanzaki S., Kawamoto K., Oh S.H., et al. From gene identification to gene therapy. Audiol Neurootol. 7:(3):2002;161-164
15. Li H., Roblin G., Liu H., et al. Generation of hair cells by stepwise differentiation of embryonic stem cells. Proc Natl Acad Sci USA. 100:(23):2003;13495-13500
16. Juhn S.K., Rybak L.P., Prado S. Nature of blood-labyrinth barrier in experimental conditions. Ann Otol Rhinol Laryngol. 90:(2 Pt 1):1981;135-141
17. Juhn S.K., Rybak L.P. Labyrinthine barriers and cochlear homeostasis. Acta Otolaryngol. 91:(5-6):1981;529-534
18. Barany R. Die Beinflussung des Ohrensausens durch intravenšs injizierte Lokalanaestetica. Acta Otlaryngol. 23:1935;201-203
19. Schuknecht H.F. Ablation therapy in the management of Meniere's disease. Acta Otolaryngol. 132:(Suppl):1957;1-42
20. Sakata E., Itoh A., Ohtsu K., et al. Pathology and treatment of cochlear tinnitus by blocking with 4% lidocaine and Decadron infusion. Practica Otologica (Kyoto). 75:1982;2525-2535
21. Weisskopf P., Hoffer M.E., Kopke R.D., et al. Microdose gentamicin delivered via the Round Window Microcathter: a therapeutic option in Meniere's disease. Oper Tech Otolaryngol Head Neck Surg. 12:2001;154-156
22. Silverstein H., Jackson L.E., Rosenberg S.I. Silverstein Microwick for the treatment of the inner ear. Operative Techniques in Otolaryngology-Head and Neck Surgery. 12:2001;144-147
23. Silverstein H., Choo D., Rosenberg S.I., et al. Intratympanic steroid treatment of inner ear disease and tinnitus (preliminary report). Ear Nose Throat J. 75:1996;468-488
24. Moskowitz D., Lee K.J., Smith H.W. Steroid use in idiopathic sudden sensorineural hearing loss. Laryngoscope. 94:(5 Pt 1):1984;664-666
25. Ariyasu L., Byl F.M., Sprague M.S., et al. The beneficial effect of methylprednisolone in acute vestibular vertigo. Arch Otolaryngol Head Neck Surg. 116:(6):1990;700-703
26. Shea J.J., Ge X. Dexamethasone perfusion of the labyrinth plus intravenous dexamethasone for Meniere's disease. Otolaryngol Clin North Am. 29:(2):1996;353-358
27. Moscicki R.A., San Martin J.E., Quintero C.H., et al. Serum antibody to inner ear proteins with progressive hearing loss. Correlation with disease activity and response to corticosteroid treatment. JAMA. 272:(8):1994;611-616
28. Parnes L.S., Sun A.H., Freeman D.J. Corticosteroid pharmacokinetics in the inner ear fluids: an animal study followed by clinical application. Laryngoscope. 109:(7 Part 2):1999;1-17
29. Shimmer B.P., Parker K.L. Adrenocorticotrophic hormone; adrenocortical steroids and their synthetic analogs; inhibitors of the synthesis and actions of adrenocortical hormones. Hardman J.G., Limbird L.E., Molinoff P.B., et al. Goodman and Gilman's the pharmacological basis of therapeutics. 9th edition :1996;1459-1485 McGraw-Hill, New York
30. Trune D.R., Kempton J.B. Aldosterone and prednisolone control of cochlear function in MRL/MpJ-Fas autoimmune mice. Hear Res. 155:(1-2):2001;9-20
31. Shirwany N.A., Seidman M.D., Tang W. Effect of transtympanic injection of steroids on cochlear blood flow, auditory sensitivity, and histology in the guinea pig. Am J Otol. 19:(2):1998;230-235
32. Tabuchi K., Oikawa K., Uemaetomari I., et al. Glucocorticoids and dehydroepiandrosterone sulfate ameliorate ischemia-induced injury of the cochlea. Hear Res. 180:(1-2):2003;51-56
33. Quirk W.S., Shapiro B.D., Miller J.M., et al. Noise induced changes in red blood cell velocity in lateral wall vessels of the rat cochlea. Hear Res. 52:(1):1991;217-223
34. Quirk W.S., Avinash G., Nuttall A.L., et al. The influence of loud sound on red blood cell velocity and vessel diameter in the cochlea. Hear Res. 63:(1-2):1992;102-107
35. Quirk W.S., Seidman M.D. Cochlear vascular changes in response to loud noise. Am J Otol. 16:(3):1995;322-325
36. Seidman M.D., Khan M.J., Dolan D.F., et al. Age related differences in cochlear microcirculation and auditory brain stem response. Arch Otolaryngol Head Neck Surg. 122:(11):1996;1221-1226
37. Suzuki T., Ren T., Nuttall A.L., et al. Age-related changes in cochlear blood flow response to occlusion of anterior inferior cerebellar artery in mice. Ann Otol Rhinol Laryngol. 107:(8):1998;648-653
38. Brown J.N., Miller J.M., Nuttall A.L. Age-related changes in cochlear vascular conductance in mice. Hear Res. 86:(1-2):1995;189-194
39. Mandal A., Kaltenbach J.A., Quirk W.S. Changes in dorsal cochlear nucleus blood flow during noise exposure. Hear Res. 106:(1-2):1997;1-8
40. Kopke R.D., Coleman J.K., Liu J., et al. Enhancing intrinsic cochlear stress defenses to reduce noise induced hearing loss. Laryngoscope. 112:(9):2002;1515-1532
41. Coyle P.K. Glucocorticoids in central nervous system bacterial infection. Arch Neurol. 56:(7):1999;796-801
42. Kaplan S.L. Prevention of hearing loss from meningitis. Lancet. 350:(9072):1997;158-159
43. Chandrasekhar S.S., Rubinstein R.Y., Kwartler J.A., et al. Dexamethasone pharmacokinetics in the inner ear: comparison of route of administration and use of facilitating agents. Otolaryngol Head Neck Surg. 122:(4):2000;521-528
44. Jackson L.E., Silverstein H. Chemical perfusion of the inner ear. Otolaryngol Clin North Am. 35:(3):2002;639-653
45. Committee on Hearing and Equilibrium. Guidelines for the diagnosis and evaluation of therapy in Meniere's disease. American Academy of Otolaryngology-Head and Neck Foundation, Inc. Otolaryngol Head Neck Surg. 113:(3):1995;181-185
46. Hillman T.M., Arriaga M.A., Chen D.A. Intratympanic steroids: do they acutely improve hearing in cases of cochlear hydrops? Laryngoscope. 113:(11):2003;1903-1907
47. Shea J.J. The role of dexamethasone or streptomycin perfusion in the treatment of Meniere's disease. Otolaryngol Clin North Am. 30:(6):1997;1051-1059
48. Kitahara T., Takeda N., Mishiro Y., et al. Effects of exposing the opened endolymphatic sac to large doses of steroids to treat intractable Meniere's disease. Ann Otol Rhinol Laryngol. 110:(2):2001;109-112
49. Dornhoffer J.L., Warner M., Arenberg I.K. Immunoperoxidase study of the endolymphatic sac in Meniere's disease. Laryngoscope. 103:(9):1993;1027-1034
50. Evans K.L., Baldwin D.L., Bainbridge D., et al. Immune-status in patients with Meniere's disease. Arch Otolaryngol. 245:(5):1988;287-292
51. Silverstein H., Isaacson J.E., Olds M.J., et al. Dexamethasone inner ear perfusion for the treatment of Meniere's disease: a prospective, randomized, double-blind, crossover trial. Am J Otol. 19:(2):1998;196-201
52. Halliwell B., Gutteridge J.M., Cross C.E. Free radicals, antioxidants, and human disease: where are we now? J Lab Clin Med. 119:(6):1992;598-620
53. Lefer A.M., Tsao P.S., Lefer D.J., et al. Role of endothelial dysfunction in the pathogenesis of reperfusion injury after myocardial ischemia. FASEB J. 5:(7):1991;2029-2034
54. Fridovich I. The biology of superoxide and of superoxide dismutase - in brief. Prog Clin Biol Res. 51:1981;153-172
55. Flohe L. The glutathione peroxidase reaction: molecular basis of the antioxidant function of selenium in mammals. Curr Top Cell Regul. 27:1985;473-478
56. Warholm M., Guthenberg C., Mannervik B., et al. Purification of a new glutathione S-transferase (transferase mu) from human liver having high activity with benzo(alpha)pyrene-4, 5-oxide. Biochem Biophys Res Commun. 98:(2):1981;512-519
57. Bieri J.G., Corash L. Hubbard VS. Medical uses of vitamin E. N Engl J Med. 308:(18):1983;1063-1071
58. Takumida M., Popa R., Anniko M. Free radicals in the guinea pig inner ear following gentamicin exposure. ORL J Otorhinolaryngol Relat Spec. 61:(2):1999;63-70
59. Yamasoba T., Nuttall A.L., Harris C., et al. Role of glutathione in protection against noise-induced hearing loss. Brain Res. 784:(1-2):1998;82-90
60. Otto W.C., Brown R.D., Gage-White L., et al. Effects of cisplatin and thiosulfate upon auditory brainstem responses of guinea pigs. Hear Res. 35:(1):1988;79-85
61. Seidman M.D., Shivapuja B.G., Quirk W.S. The protective effects of allopurinol and superoxide dismutase on noise induced cochlear damage. Otolaryngol Head Neck Surg. 109:(6):1993;1052-1056
62. Sinswat P., Wu W.J., Sha S.H., et al. Protection from ototoxicity of intraperitoneal gentamicin in guinea pig. Kidney Int. 58:(6):2000;2525-2532
63. Yamane H., Nakai Y., Takayama M., et al. Appearance of free radicals in the guinea pig inner ear after noise-induced acoustic trauma. Eur Arch Otorhinolaryngol. 252:(8):1995;504-508
64. Ohlemiller K.K., McFadden S.L., Ding D.L., et al. Targeted deletion of the cytosolic Cu/Zn-superoxide dismutase gene (Sod 1) increases susceptibility to noise induced hearing loss. Audiol Neurootol. 4:(5):1999;237-246
65. Sha S.H., Schacht J. Prevention of aminoglycoside induced hearing loss. Keio J Med. 46:(3):1997;115-119
66. Fetoni A.R., Sergi B., Scarano E., et al. Protective effects of alpha-tocopherol against gentamicin-induced oto-vestibulo toxicity: an experimental study. Acta Otolaryngol. 123:(2):2003;192-197
67. Clerici W.J. Effects of superoxide dismutase and U74389G on acute trimethyltin induced cochlear dysfunction. Toxicol Appl Pharmacol. 136:(2):1996;236-242
68. Anderson M.E. Glutathione: an overview of biosynthesis and modulation. Chem Biol Interact. 111-112:1998;1-14
69. Meister A. Selective modification of glutathione metabolism. Science. 220:(4596):1983;472-477
70. Habig W.H., Pabst M.J., Jakoby W.B. Glutathione S-transferases. The first enzymatic step in mercapturic acid formation. J Biol Chem. 249:(22):1974;7130- 7139
71. Reed D.J., Savage M.K. Influence of metabolic inhibitors on mitochondrial permeability transition and glutathione status. Biochim Biophys Acta. 1271:(1):1995;43-50
72. Hoffman D.W., Wiebkin P., Rybak L.P. Inhibition of glutathione related enzymes and cytotoxicity of ethacrynic acid and cyclosporine. Biochem Pharmacol. 49:(3):1995;411-415
73. Huang M.Y., Schacht J. Formation of a cytotoxic metabolite from gentamicin by liver. Biochem Pharmacol. 40:(11):1990;R11-R14
74. Zenner H.P., Keiner S., Zimmerman U. Specific glutathione-SH inhibition of toxic effects of metabolized gentamicin on isolated guinea pig hair cells. Eur Arch Otorhinolaryngol. 251:(1):1994;61-64
75. Drew R., Miners J.O. The effects of buthionine sulphoximine (BSO) on glutathione depletion and xenobiotic biotransformation. Biochem Pharmacol. 33:(19):1984;2989-2994
76. Unnikrishnan M.K., Rao M.N. Antiinflammatory activity of methionine, methionine sulfoxide and methionine sulfone. Agents Actions. 31:(1-2):1990;110-112
77. Dawson R.M., Elliot D.C., Elliot W.H., et al. Metal binding properties of compounds used in biochemistry. Dawson R.M., Elliot D.C., Elliot W.H., et al. Data for biochemical research. 3rd edition :1986;409 Oxford Publications, Oxford (UK)
78. Sha S.H., Schacht J. Antioxidants attenuate gentamicin-induced free radical formation in vitro and ototoxicity in vivo: D-methionine is a potential protectant. Hear Res. 142:(1-2):2000;34-40
79. Kopke R.D., Liu W., Gabaizadeh R., et al. Use of organotypic cultures of Corti's organ to study the protective effects of antioxidant molecules on cisplatin induced damage of auditory hair cells. Am J Otol. 18:(5):1997;559-571
80. Campbell K.C., Rybak L.P., Meech R.P., et al. D-methionine provides excellent protection from cisplatin ototoxicity in the rat. Hear Res. 102:(1-2):1996;90-98
81. Li G., Frenz D.A., Brahmblatt S., et al. Round window membrane delivery of L-methionine provides protection from cisplatin ototoxicity without compromising chemotherapeutic efficacy. Neurotoxicology. 22:(2):2001;163-176
82. Lockwood D.S., Ding D.L., Wang J., et al. D-methionine attenuates inner hair cell loss in carboplatin-treated chinchillas. Audiol Neurootol. 5:(5):2000;263-266
83. Wimmer C., Mees K., Stumpf P., et al. Round window application of D-methionine, sodium thiosulfate, brain-derived neurotrophic factor, and fibroblast growth factor-2 in cisplatin-induced ototoxicity. Otol Neurotol. 25:(1):2004;33-40
84. Anderson M.E. Glutathione: an overview of biosynthesis and modulation. Chem Biol Interact. 111-112:1998;1-14
85. Meister A. Glutathione deficiency produced by inhibition of its synthesis, and its reversal; applications in research and therapy. Pharmacol Ther. 51:(2):1991;155-194
86. Kopke R.D., Weisskopf P.A., Boone J.L., et al. Reduction of noise-induced hearing loss using L-NAC and salicylate in the chinchilla. Hear Res. 149:(1-2):2000;138-146
87. Klein M., Koedel U., Pfister H.W., et al. Meningitis-associated hearing loss: protection by adjunctive antioxidant therapy. Ann Neurol. 54:(4):2003;451-458
88. Belguendouz L., Fremont L., Linard A. Resveratrol inhibits metal ion-dependent and independent peroxidation of porcine low-density lipoproteins. Biochem Pharmacol. 53:(9):1997;1347-1355
89. Chanvitayapongs S., Draczynska-Lusiak B., Sun A.Y. Amelioration of oxidative stress by antioxidants and resveratrol in PC12 cells. Neuroreport. 8:(6):1997;1499-1502
90. Pace-Asciak C.R., Hahn S., Diamandis E.P., et al. The red wine phenolics trans-resveratrol and quercetin block human platelet aggregation and eicosanoid synthesis: implications for protection against coronary heart disease. Clin Chim Acta. 235:(2):1995;207-219
91. Bertelli A.A., Giovannini L., Giannessi D., et al. Antiplatelet activity of synthetic and natural resveratrol in red wine. Int J Tissue React. 17:(1):1995;1-3
92. Chen C.K., Pace-Asciak C.R. Vasorelaxing activity of resveratrol and quercetin in isolated rat aorta. Gen Pharmacol. 27:(2):1996;363-366
93. Seidman M.D., Babu S., Tang W., et al. Effects of resveratrol on acoustic trauma. Otolaryngol Head Neck Surg. 129:(5):2003;463-470
94. Bradley J.R., Johnson D.R., Pober J.S. Endothelial activation by hydrogen peroxide. Selective increases of intercellular adhesion molecule-1 and major histocompatibility complex class I. Am J Pathol. 142:(5):1993;1598-1609
95. Morita Y., Clemens M.G., Miller L.S., et al. Reactive oxidants mediate TNF-alpha-induced leukocyte adhesion to rat mesenteric venular endothelium. Am J Physiol. 269:(Pt2):1995;H1833-H1842
96. Coletti J., Suresh Babu V., Pavlovic A.S., et al. Localized moment in Mn-doped gamma-TiAl alloys. Phys Rev B Condens Matter. 42:1990;10754-10757
97. Minami M., Kuraishi Y., Yabuuchi K., et al. Induction of interleukin-1 beta mRNA in rat brain after transient forebrain ischemia. J Neurochem. 58:(1):1992;390-392
98. Shreeniwas R., Koga S., Karakurum M., et al. Hypoxia-mediated induction of endothelial cell interleukin-1 alpha. An autocrine mechanism promoting expression of leukocyte adhesion molecules on the vessel surface. J Clin Invest. 90:(6):1992;2333-2339
99. Shoskes D.A., Halloran P.F. Ischemic injury induces altered MHC gene expression in kidney by an interferon-gamma-dependent pathway. Transplant Proc. 23:(Pt1):1991;599-601
100. Rothlein R., Jaeger J.R. Treatment of inflammatory diseases with a monoclonal antibody to intercellular adhesion molecules 1. Ciba Found Symp. 189:1995;200-208. [discussion 208-11]
101. Bonventre J.V., Kelly K.J. Adhesion molecules and acute renal failure. Adv Nephrol Necker Hosp. 25:1996;159-176
102. rd Annual Midwinter Research Meeting for Research in Otolaryngology. St. Petersburg (FL), February 20-24, 2000.
103. Hyde G.E., Rubel E.W. Mitochondrial role in hair cell survival after injury. Otolaryngol Head Neck Surg. 113:(5):1995;530-540
104. Seidman M.D., Bai U., Khan M.J., et al. Association of mitochondrial DNA deletions and cochlear pathology: a molecular biologic tool. Laryngoscope. 106:(6):1996;777-783
105. Seidman M.D., Khan M.J., Bai U., et al. Biologic activity of mitochondrial metabolites on aging and age related hearing loss. Am J Otol. 21:(2):2000;161-167
106. Seidman M.D., Khan M.J., Tang W.X., et al. Influence of lecithin on mitochondrial DNA and age related hearing loss. Otolaryngol Head Neck Surg. 127:(3):2002;138-144
107. Gadaleta M.N., Cormio A., Pesce V., et al. Aging and mitochondria. Biochimie. 80:(10):1998;863-870
108. Shigenaga M.K., Hagen T.M., Ames B.N. Oxidative damage and mitochondrial decay in aging. Proc Natl Acad Sci U S A. 91:(23):1994;10771-10778
109. Conlon B.J., Aran J.M., Erre J.P., et al. Attenuation of aminoglycoside-induced cochlear damage with the metabolic antioxidant alpha-lipoic acid. Hear Res. 128:(1-2):1999;40-44
110. Nordang L., Cestreicher E., Arnold W., et al. Glutamate is the afferent neurotransmitter in the human cochlea. Acta Otolaryngol. 120:(3):2000;359-362
111. Rothman S.M., Olney J.W. Glutamate and the pathophysiology of hypoxic-ischemic brain damage. Ann Neurol. 19:(2):1986;105-111
112. Rothman S.M., Olney J.W. Excitotoxicity and the NMDA receptor - still lethal after eight years. Trends Neurosci. 18:(2):1995;57-58
113. Duan M.L., Ulfendahl M., Laurell G., et al. Protection and treatment of sensorineural hearing disorders caused by exogenous factors: experimental findings and potential clinical applications. Hear Res. 169:(1-2):2002;169-178
114. Khan M.J., Seidman M.D., Quirk W.S., et al. Effects of kynurenic acid as a glutamate receptor antagonist in the guinea pig. Eur Arch Otorhinolaryngol. 257:(4):2000;177-181
115. Basile A.S., Huang J.M., Xie C., et al. N-methyl-D-aspartate antagonists limit aminoglycoside antibiotic-induced hearing loss. Nat Med. 2:(12):1996;1338-1343
116. Chen G.D., Kong J., Reinhard K., et al. NMDA receptor blockage protects against permanent noise-induced hearing loss but not its potentiation by carbon monoxide. Hear Res. 154:(1-2):2001;108-115
117. Duan M., Agerman K., Ernfors P., et al. Complementary roles of neurotrophin 3 and a N-methyl-D-aspartate antagonist in the protection of noise and aminoglycoside-induced ototoxicity. Proc Natl Acad Sci U S A. 97:(13):2000;7597-7602
118. Sekiya T., Shimamura N., Hatayama T., et al. Effectiveness of preoperative administration of an N-methyl-D-aspartate antagonist to enhance cochlear neuron resistance to intraoperative traumatic stress: an experimental study. J Neurosurg. 93:(1):2000;90-98
119. Oestreicher E., Arnold W., Ehrenberger K., et al. New approaches for inner ear therapy with glutamate antagonists. Acta Otlaryngol. 119:(2):1999;174-178
120. Denk D.M., Heinzl H., Franz P., et al. Caroverine in tinnitus treatment. A placebo contolled blind study. Acta Otolaryngol. 117:(6):1997;825-830
121. Attias J., Weisz G., Almog S., et al. Oral magnesium intake reduces permanent hearing loss induced by noise exposure. Am J Otolaryngol. 15:(1):1994;26-32
122. Chen Z., Ulfendahl M., Ruan R., et al. Acute treatment of noise trauma with local caroverine application in the guinea pig. Acta Otolaryngol. 123:(8):2003;905-909
123. Puel J.L., Gervais C., d'Aldin G., et al. Excitotoxicity and plasticity of IHC-auditory nerve contributes to both temporary and permanent threshold shift. Axelsson A., Borchegrevink H., Hamernik R.P., et al. Scientific basis of noise-induced hearing loss. 1996;36-42 George Thieme Verlag, New York
124. Puel J.L., Pujol R., Ladrech S., et al. Alpha-amino-3-hydroxy-5-methyl-4- isoxazole propionic acid electrophysiological and neurotoxic effects in the guinea-pig cochlea. Neuroscience. 45:(1):1991;63-72
125. Pujol R., Lenoir M., Robertson D., et al. Kainic acid selectively alters auditory dendrites connected with cochlear inner hair cells. Hear Res. 18:(2):1985;145-151
126. Puel J.L., Pujol R., Tribillac F., et al. Excitatory amino acid antagonists protect cochlear auditory neurons from excitotoxicity. Neuroscience. 341:(2):1994;241-256
127. Kampfl A., Posmantur R.M., Zhao X., et al. Mechanism of calpain proteolysis following traumatic brain injury: implications for pathology and therapy: a review and update. J Neurotrauma. 14:(3):1997;121-134
128. Tang W., Seidman M.D., Henij J.P., et al. The effects on leupeptin on cochlear blood flow, auditory sensitivity, and histology. Int Tinnitus J. 7:(1):2001;4-12
129. Zimmerman U.J., Schlaepfer W.W. Calcium-activated neutral protease (CANP) in brain and other tissues. Prog Neurobiol. 23:(1-2):1984;63-78
130. Saito K., Elce J.S., Hamos J.E., et al. Widespread activation of calcium-activated neutral proteinase (calpain) in the brain in Alzheimer disease: a potential molecular basis for neuronal degeneration. Proc Natl Acad Sci U S A. 90:(7):1993;2628-2632
131. Banik N.L., Shields D.C., Ray S., et al. Role of calpain in spinal cord injury: effects of calpain and free radical inhibitors. Ann N Y Acad Sci. 844:1998;131-137
132. st Annual Midwinter Research Meeting of the Association for Research in Otolaryngology. St. Petersburg (FL), February 15-19, 1998.
133. Nishimoto SY, Hughes RM, Faddis BT. Activation of calpain in the cochlea following noise exposure. Presented at a poster session during the 22nd Annual Midwinter Research Meeting of the Association for Research in Otolaryngology. St. Petersburg (FL), February 13-18, 1999.
134. Stracher A. Calpain inhibitors as neuroprotective agents in neurodegenerative disorders. Int Tinnitus J. 3:(2):1997;71-75
135. Shulman A. Noise, calpain, calpain inhibitors, and neuroprotection: a preliminary report of tinnitus control. Int Tinnitus J. 4:(2):1998;134-140
136. Ding L., McFadden S.L., Salvi R.J. Calpain immunoreactivity and morphological damage in chinchilla inner ears after carboplatin. J Assoc Res Otolaryngol. 3:(1):2002;68-79
137. Cheng A.G., Huang T., Stracher A., et al. Calpain inhibitors protect auditory sensory cells from hypoxia and neurotrophin-withdrawal induced apoptosis. Brain Res. 850:(1-2):1999;234-243
138. Salvi R.J., Shulamn A., Stracher A., et al. protecting inner ear from acoustic trauma. Int Tinnitus J. 4:(1):1998;11-15
139. Ding D., Stracher A., Salvi R.J. Leupeptin protects cochlear and vestibular hair cells from gentamicin ototoxicity. Hear Res. 164:(1-2):2002;115-126
140. Staecker H., Van De Water T.R. Factors controlling hair-cell regeneration/repair in the inner ear. Curr Opin Neurobiol. 8:(4):1998;480-487
141. Lefebvre P.P., Malgrange B., Thiry M., et al. Epidermal growth factor upregulates production of supernumerary hair cells in neonatal rat organ of Corti explants. Acta Otolaryngol. 120:(2):2000;142-145
142. Gao W.Q. Role of neurotrophins and lectins in prevention of ototoxicity. Ann N Y Acad Sci. 884:1999;312-327
143. Altschuler R.A., Cho Y., Ylikoski J., et al. Rescue and regrowth of sensory nerves following differentiation by neurotrophic factors. Ann N Y Acad Sci. 884:1999;305-311
144. Ernfors P., Duan M.L., El Shamy W.M., et al. Protection of auditory neurons from aminoglycoside toxicity by neurotrophin-3. Nat Med. 2:(4):1996;463-476
145. Ylikoski J., Pirvola U., Virkkala J., et al. Guinea pig auditory neurons are protected by glial cell line-derived growth factor from degeneration after noise. Hear Res. 124:(1-2):1998;17-26
146. Ruan R.S., Leong S.K., Mark I., et al. Effects of BDNF and NT-3 on hair cell survival in guinea pig cochlea damaged by kanamycin treatment. Neuroreport. 10:(10):1999;2067-2071
147. Keithley E.M., Ma C.L., Ryan A.F., et al. GDNF protects the cochlea against noise damage. Neuroreport. 9:(10):1998;2183-2187
148. Shoji F., Yamasoba T., Magal E., et al. Glial cell line-derived neurotrophic factor has a dose dependent influence on noise induced hearing loss in the guinea pig cochlea. Hear Res. 142:(1-2):2000;41-55
149. Shoji F., Miller A.L., Mitchell A., et al. Differential protective effects of neurotrophins in the attenuation of noise-induced hair cell loss. Hear Res. 146:(1-2):2000;134-142
150. Zou J., Bretlau P., Pyykko I., et al. Comparison of the protective efficacy of neurotrophins and antioxidants for vibration-induced trauma. ORL J Otorhinolaryngol Relat Spec. 65:(3):2003;155-161
151. Shinohara T., Bredberg G., Ulfendahl M., et al. Neurotrophic factor intervention restores auditory function in deafened animals. Proc Natl Acad Sci U S A. 99:(3):2002;1657-1660
152. Van de Water T.R., Staecker H., Halterman M.W., et al. Gene therapy in the inner ear. Mechanisms and clinical implications. Ann N Y Acad Sci. 884:1999;345-360
153. Kawamoto K., Sha S.H., Minoda R., et al. Antioxidant gene therapy can protect hearing and hair cells from ototoxicity. Mol Ther. 9:(2):2004;173-181
154. Kawamoto K., Yagi M., Stover T., et al. Hearing and hair cells are protected by adenoviral gene therapy with TGF-beta1 and GDNF. Mol Ther. 7:(4):2003;484-492
155. Hakuba N., Watabe K., Hyodo J., et al. Adenovirus-mediated overexpression of a gene prevents hearing loss and progressive inner hair cell loss after transient cochlear ischemia in gerbils. Gene Ther. 10:(5):2003;426-433
156. Li Duan M., Bordet T., Mezzina M., et al. Adenoviral and adeno-associated viral vector mediated gene transfer in the guinea pig cochlea. Neuroreport. 13:(10):2002;1295-1299
157. Yagi M., Kanzaki S., Kawamoto K., et al. Spiral ganglion neurons are protected from degeneration by GDNF gene therapy. J Assoc Res Otolaryngol. 1:(4):2000;315-325
158. Suzuki M., Yagi M., Brown J.N., et al. Effect of transgenic GDNF expression on gentamicin-induced cochlear and vestibular toxicity. Gene Ther. 7:(12):2000;1046-1054
159. Wareing M., Mhatre A.N., Pettis R., et al. Cationic liposome mediated transgene expression in the guinea pig cochlea. Hear Res. 128:(1-2):1999;61-69
160. Jero J., Tseng C.J., Mhatre A.N., et al. A surgical approach appropriate for targeted cochlear gene therapy in the mouse. Hear Res. 151:(1-2):2001;106- 114
161. Kanzaki S., Stover T., Kawamoto K., et al. Glial cell line-derived neurotrophic factor and chronic electrical stimulation prevent VIII cranial nerve degeneration following denervation. J Comp Neurol. 454:(3):2002;350-360
162. Kawamoto K., Ishimoto S., Minoda R., et al. Math1 gene transfer generates new cochlear hair cells in mature guinea pigs in vivo. J Neurosci. 23:(11):2003;4395-4400
163. Chen X., Frisina R.D., Bowers W.J., et al. HSV amplicon-mediated neurotrophin-3 expression protects murine spiral ganglion neurons from cisplatin-induced damage. Mol Ther. 3:(6):2001;958-963
164. Bowers W.J., Chen X., Guo H., et al. Neurotrophin-3 transduction attenuates cisplatin spiral ganglion neuron ototoxicity in the cochlea. Mol Ther. 6:(1):2002;12-18